Testing effectiveness (Phase 2)WithdrawnNCT00678626What this trial is testingPhase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast CancerWho this might be right forBreast Cancer Pfizer
Testing effectiveness (Phase 2)Active Not RecruitingNCT04544189What this trial is testingStudy Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast CancerWho this might be right forBreast Neoplasms Novartis Pharmaceuticals 69
Testing effectiveness (Phase 2)Looking for participantsNCT07180160What this trial is testingIparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast CancerWho this might be right forAdvanced Breast Cancer Wenjin Yin 123
Large-scale testing (Phase 3)Ended earlyNCT01303679What this trial is testing1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast CancerWho this might be right forFirst Line Metastatic Breast Cancer ARCAGY/ GINECO GROUP 117
Testing effectiveness (Phase 2)Active Not RecruitingNCT04576455What this trial is testingA Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)Who this might be right forEstrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Hoffmann-La Roche 303
Early research (Phase 1)WithdrawnNCT01333423What this trial is testingMaximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)Who this might be right forBreast Cancer M.D. Anderson Cancer Center
Post-approval studies (Phase 4)Not Yet RecruitingNCT07162259What this trial is testingCohort Study on Sequential ADC Therapy in HR-positive/HER2-negative Advanced Breast CancerWho this might be right forBreast Neoplasms Yan Xue 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07151586What this trial is testingTesting Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast CancerWho this might be right forTriple Negative Breast NeoplasmsNeoplasm MetastasisHER 2 Low-expressing Breast Cancer UNICANCER 260
Early research (Phase 1)Looking for participantsNCT05870579What this trial is testing[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerWho this might be right forBreast Cancer Novartis Pharmaceuticals 48
Testing effectiveness (Phase 2)Looking for participantsNCT05810870What this trial is testingPIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With EribulinWho this might be right forBreast CancerAdvanced Breast CancerMetastatic Breast Cancer MedSIR 14
Early research (Phase 1)WithdrawnNCT01320787What this trial is testing18-F-Fluoroacetate as PET Imaging AgentWho this might be right forBrain CancerBreast CancerProstate Cancer M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT04585750What this trial is testingThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Who this might be right forAdvanced Solid TumorAdvanced Malignant NeoplasmMetastatic Cancer+27 more PMV Pharmaceuticals, Inc 300
Early research (Phase 1)Looking for participantsNCT04389632What this trial is testingSigvotatug Vedotin in Advanced Solid TumorsWho this might be right forCarcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more Seagen, a wholly owned subsidiary of Pfizer 1,006
Early research (Phase 1)Looking for participantsNCT06121557What this trial is testingPhase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerWho this might be right forBreast Neoplasms Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT03911973What this trial is testingGedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast CancersWho this might be right forTNBC - Triple-Negative Breast Cancer Kari Wisinski 37
Not applicableStudy completedNCT06686602What this trial is testingA Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast CancerWho this might be right forAdvanced/Metastatic NSCLCAdvanced/Metastatic HER2-negative Breast Cancer Daiichi Sankyo 13,759
Early research (Phase 1)Looking for participantsNCT07369505What this trial is testingSapu003 in Advanced mTOR-sensitive Solid TumorsWho this might be right forBreast Cancer MetastaticRenal Cell Carcinoma (RCC)Neuroendocrine Tumors+2 more SAPU NANO (US) LLC 27
Testing effectiveness (Phase 2)Looking for participantsNCT06840483What this trial is testingStudy of Zelenectide Pevedotin in Participants With Advanced Breast CancerWho this might be right forBreast Cancer BicycleTx Limited 66
Testing effectiveness (Phase 2)Looking for participantsNCT05660083What this trial is testingAlpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)Who this might be right forHER2-negative Breast CancerMetastatic Breast CancerMetaplastic Breast Carcinoma+1 more The Methodist Hospital Research Institute 36
Testing effectiveness (Phase 2)UnknownNCT04488107What this trial is testingSafety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437cWho this might be right forBreast Neoplasms Ahon Pharmaceutical Co., Ltd. 78